Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EN41-FPA2 HIV vaccine
- Development stage
- Phase 1
- Lead developer
- PX'Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intranasal, Intramuscular
01
Overview
EN41-FPA2 is a peptide-based HIV-1 vaccine candidate developed as part of the European EuroNeut-41 consortium. The vaccine consists of a 65-amino acid synthetic peptide derived from the membrane-proximal external region (MPER) of the HIV-1 envelope glycoprotein gp41. It is designed to elicit neutralizing antibodies, specifically mucosal IgA and systemic IgG, to block HIV-1 entry at the mucosal surface and neutralize viral particles. In clinical development, EN41-FPA2 has been evaluated in Phase 1 trials using a prime-boost strategy involving intranasal priming followed by intramuscular boosting, often formulated with virosomes or other delivery systems to enhance immunogenicity.
- Other names
- EN41-FPA2EN-41-FPA2EN 41-FPA2gp41-derived HIV-1 vaccinegp-41-derived HIV-1 vaccinegp 41-derived HIV-1 vaccineEuroNeut-41 vaccineEuroNeut41 vaccineEuroNeut 41 vaccine
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on EN41-FPA2 HIV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EN41-FPA2 HIV vaccine.